• PDF / 237,184 Bytes
• 18 Pages / 439.37 x 666.142 pts Page_size
• 108 Downloads / 163 Views

DOWNLOAD

REPORT

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2906

2 2.1 2.2 2.2.1 2.2.2 2.2.3

Treatment for Advanced RCC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2907 Cytokine Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2907 Targeted Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2910 Multikinase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2910 Anti-Vascular Endothelial Growth Factor Anti-Bodies . . . . . . . . . . . . . . . . . . . . . . . . . . . 2911 Mammalian Target of Rapamycin Inhibitors (mTOR) . . . . . . . . . . . . . . . . . . . . . . . . . . . 2911

3 3.1 3.2

Quality of Life . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2912 Assessment of PRO Using Validated Questionnaires . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2912 Evaluation of Change in Symptom Response/QoL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2912

4 4.1

Quality of Life in Advanced RCC Patient . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2914 Effects of Cytokine Therapy and Other Non-Targeted Agents on Quality of Life . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2914 4.2 Effect of Targeted Therapy on Quality of Life . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2917 4.2.1 Mutikinase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2917 4.2.2 Mammalian Target of Rapamycin (mTOR) Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . 2919 5

Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2919 Summary Points . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2920 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2920

#

Springer Science+Business Media LLC 2010 (USA)

2906

169

Quality of Life in Advanced Renal Cell Carcinoma

Abstract: Renal Cell Carcinoma (RCC) is the most common type of kidney cancer and its’ incidence is increasing steadily worldwide. Due to the asymptomatic nature of the disease it is often diagnosed in advanced stages and treatment options have been limited. Symptoms of the advanced disease along with side-effects of available treatment options can

Recommend Documents

Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma

175 91 178KB

Temisorlimus in the treatment of advanced renal cell carcinoma

155 57 121KB

Targeted Therapies for Treatment of Metastatic Renal Cell Carcinoma

165 11 7MB

Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma

153 41 1MB

Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma:

154 5 461KB

The role of income disparities on survival in metastatic clear cell renal cell carcinoma in the targeted therapy era

152 30 3MB

Treatment-Related Optimism Protects Quality of Life in a Phase II Clinical Trial for Metastatic Renal Cell Carcinoma

140 64 204KB

Surgical Approaches to Treatment of Renal Cell Carcinoma

165 102 34MB

Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carci

144 95 744KB

Evaluation and treatment results of trimodality therapy for advanced esophageal squamous cell carcinoma

170 78 812KB

Renal Cell Carcinoma

177 106 514KB

Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers

146 38 13MB